Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals develops and commercializes products for central nervous system diseases. Commercial products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. Product candidates include SPN-830, SPN-817, SPN-820, SPN-443, SPN-446, and SPN-448. The company markets products through wholesalers, specialty pharmacies, and distributors. It was incorporated in 2005 and is headquartered in Rockville, Maryland.
Overview
Strengths
- Pricing power: gross margin has held between 86% and 90% over the last 6 years (latest 89.6%).
- Asset-light, cash-generative model: capital expenditure takes only 0.2% of revenue and free cash flow was positive in each of the last 6 years.
- Net cash balance sheet: cash exceeds total debt.
Weaknesses
- Currently loss-making: the latest fiscal year closed with a net loss.
- Our discounted cash flow target price (11.38 USD) is 57% below the current price.
- Unstable profitability: operating margin ranged from -5% to 34% over the last 6 years, with operating losses in 1 of them.
- Valued at a premium to its Drug Manufacturers - Specialty & Generic peers: P/FCF 33.4x vs. a median of 16.5x and EV/EBITDA 21.3x vs. a median of 12.5x.
- Earnings are projected to decline (-10.0% per year).
- ROIC of 4.3% trails 78% of its 55 Drug Manufacturers - Specialty & Generic peers (median 11.0%).
Key Financial Data